MARKET

APVO

APVO

Aptevo
NASDAQ

Real-time Quotes | Nasdaq Last Sale

45.55
-0.08
-0.18%
Closed 19:58 11/23 EST
OPEN
45.48
PREV CLOSE
45.63
HIGH
45.56
LOW
42.29
VOLUME
231.37K
TURNOVER
--
52 WEEK HIGH
60.00
52 WEEK LOW
2.940
MARKET CAP
188.81M
P/E (TTM)
-4.4899
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
The Daily Biotech Pulse: Amarin Surges On Vascepa Data, Mesoblast Rallies On Novartis Deal, Decision Day For Eiger
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 19)
Benzinga · 3d ago
Aptevo Confirms Confirms Receipt Of Unsolicited Non-Binding Indication Of Interest From Tang Capital Partners To Acquire All Aptevo Shares It Does Not Down For $50/Share In Cash; Co. Will 'carefully evaluate and consider this indication of interest'
biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ bispecific technology platform, today announced that it has received an unsolicited non-binding
Benzinga · 4d ago
Mid-Afternoon Market Update: S&P 500 Turns Positive; Medigus Shares Spike Higher
Toward the end of trading Thursday, the Dow traded down 0.06% to 29,421.88 while the NASDAQ rose 0.66% to 11,878.98. The S&P also rose, gaining 0.21% to 3,575.44.
Benzinga · 4d ago
GPRO, BLNK, MGTX and SONO among midday movers
Gainers: Naked Brand (NAKD) +116%.Phoenix New Media (FENG) +48%.Titan Pharmaceuticals (TTNP) +36%.HighPoint Resources (HPR) +32%.Arcimoto (FUV) +32%.Ayro (AYRO) +29%.CIIG Merger (CIIC) +27%.Aptevo Therapeutics (APVO) +27%.Sonos (SONO) +27%.Blink Charging (BLNK) +23%.Losers: Ebang International
Seekingalpha · 4d ago
Mid-Day Market Update: Nasdaq Rises 50 Points; MeiraGTx Shares Plunge
Midway through trading Thursday, the Dow traded down 0.45% to 29,305.90 while the NASDAQ rose 0.45% to 11,854.51. The S&P also fell, dropping 0.21% to 3,560.41.
Benzinga · 4d ago
Medigus, Aptevo Therapeutics leads healthcare gainers; MeiraGTx Holdings, Kintara Therapeutics among major losers
Gainers: Medigus (MDGS) +30%, Aptevo Therapeutics (APVO) +29%, Corcept Therapeutics (CORT) +23%, Opiant Pharmaceuticals (OPNT) +15%, Aquestive Therapeutics (AQST) +11%.Losers: MeiraGTx Holdings (MGTX) -11%, Kintara Therapeutics (KTRA) -10%, Berkeley Lights (BLI) -10%, Kazia Therapeutics (KZIA) -8%, Immutep (IMMP) -7%.
Seekingalpha · 4d ago
Mid-Morning Market Update: Markets Mixed; Macy's Posts Narrower-Than-Expected Loss
Following the market opening Thursday, the Dow traded down 0.21% to 29,375.58 while the NASDAQ rose 0.21% to 11,826.72. The S&P also fell, dropping 0.18% to 3,561.54.
Benzinga · 4d ago
LB, YY, BERY and NKLA among premarket gainers
Phoenix New Media (FENG) +62% after announcing special distribution.Hudson Capital (HUSN) +37%.Aptevo Therapeutics (APVO) +31% following a disclosure that 42.5% shareholder Tang Capital Partners offered to buy the remaining shares for $50/share in cash.Corcept
Seekingalpha · 4d ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of APVO. Analyze the recent business situations of Aptevo through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average APVO stock price target is 65.67 with a high estimate of 69.00 and a low estimate of 64.00.
EPS
Institutional Holdings
Institutions: 60
Institutional Holdings: 8.59M
% Owned: 207.28%
Shares Outstanding: 4.15M
TypeInstitutionsShares
Increased
4
80.53K
New
11
-35.16K
Decreased
6
18.24K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About APVO
Aptevo Therapeutics Inc. is a biotechnology company. The Company is focused on oncology and hematology therapeutics. The Company is engaged in the discovery, development, commercialization and sale of oncology and hematology therapeutics. The Company's technology is the ADAPTIR (modular protein technology) platform. The Company has approximately four products in the areas of hematology and infectious diseases, as well as various investigational-stage product candidates in immuno-oncology. The Company's investigational-stage product candidates include MOR209/ES414, ES210, ES425, Otlertuzumab and 5E3. Its technology can produce monospecific and multispecific immunotherapeutic proteins that bind to various targets. The Company's marketed products are WinRho SDF (Rho(D) Immune Globulin Intravenous (Human)), HepaGam B (Hepatitis B Immune Globulin Intravenous (Human)) and VARIZIG (Varicella Zoster Immune Globulin (Human)).
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Aptevo Therapeutics Inc stock information, including NASDAQ:APVO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, APVO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading APVO stock methods without spending real money on the virtual paper trading platform.